Cumulative incidence of post-infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis.
Asthma
/ epidemiology
Child, Preschool
Databases, Factual
Female
Follow-Up Studies
Hospitalization
/ statistics & numerical data
Humans
Incidence
Infant
Infant, Newborn
Male
Respiratory Sounds
/ etiology
Respiratory Syncytial Virus Infections
/ complications
Respiratory Syncytial Virus, Human
/ pathogenicity
Retrospective Studies
Risk Factors
United States
/ epidemiology
asthma
cumulative incidence
infants
pre-existing high-risk factors
respiratory syncytial virus
wheezing
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
20
12
2019
accepted:
24
05
2020
pubmed:
14
6
2020
medline:
20
7
2021
entrez:
14
6
2020
Statut:
ppublish
Résumé
Respiratory syncytial virus (RSV) infection is implicated in subsequent development of asthma/wheezing (AW) among term and pre-term infants. We describe the cumulative incidence of AW among hospitalized and ambulatory neonates/infants/toddlers following RSV infection diagnosis over three independent follow-up periods. Between January 1, 2007 and March 31, 2016, patients aged 0-2 years old with first clinical diagnosis of RSV infection were identified using the Optum Overall, 9811, 4524, and 1788 RSV-infected high-risk factor negative patients were included in 1, 3, and 5-year independent cohorts, respectively. Of these, 6.5%, 6.9%, and 5.8%, respectively had RSV-related hospitalization. By the end of follow-up, 14.9%, 28.2%, and 36.3% had AW events. Overall, 3030, 1378, and 552 RSV-infected high-risk factor positive patients were included in the respective cohorts. Of these, 11.4%, 11.1%, and 11.6%, respectively were hospitalized with initial RSV infection and 18.1%, 32.9%, and 37.9% had subsequent AW events within the follow-up period. Logistic regression confirmed RSV-related hospitalization significantly increased the likelihood of developing AW (P < .05) in high-risk factor positive and negative patients. In infants diagnosed with RSV infection, RSV-related hospitalization was associated with a significantly increased likelihood of AW development for at least 5 years, compared with non-hospitalized patients.
Sections du résumé
BACKGROUND
Respiratory syncytial virus (RSV) infection is implicated in subsequent development of asthma/wheezing (AW) among term and pre-term infants. We describe the cumulative incidence of AW among hospitalized and ambulatory neonates/infants/toddlers following RSV infection diagnosis over three independent follow-up periods.
METHODS
Between January 1, 2007 and March 31, 2016, patients aged 0-2 years old with first clinical diagnosis of RSV infection were identified using the Optum
RESULTS
Overall, 9811, 4524, and 1788 RSV-infected high-risk factor negative patients were included in 1, 3, and 5-year independent cohorts, respectively. Of these, 6.5%, 6.9%, and 5.8%, respectively had RSV-related hospitalization. By the end of follow-up, 14.9%, 28.2%, and 36.3% had AW events. Overall, 3030, 1378, and 552 RSV-infected high-risk factor positive patients were included in the respective cohorts. Of these, 11.4%, 11.1%, and 11.6%, respectively were hospitalized with initial RSV infection and 18.1%, 32.9%, and 37.9% had subsequent AW events within the follow-up period. Logistic regression confirmed RSV-related hospitalization significantly increased the likelihood of developing AW (P < .05) in high-risk factor positive and negative patients.
CONCLUSIONS
In infants diagnosed with RSV infection, RSV-related hospitalization was associated with a significantly increased likelihood of AW development for at least 5 years, compared with non-hospitalized patients.
Identifiants
pubmed: 32533658
doi: 10.1111/irv.12770
pmc: PMC7578296
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
730-738Informations de copyright
© 2020 Janssen Research and Development. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Pediatr Allergy Immunol. 2005 Aug;16(5):386-92
pubmed: 16101930
Am J Respir Crit Care Med. 2017 Jul 1;196(1):29-38
pubmed: 28152315
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Expert Rev Anti Infect Ther. 2011 Sep;9(9):731-45
pubmed: 21905783
Pediatr Rev. 2014 Dec;35(12):519-30
pubmed: 25452661
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
Lancet Respir Med. 2018 Apr;6(4):257-264
pubmed: 29500030
Am J Respir Crit Care Med. 2000 May;161(5):1501-7
pubmed: 10806145
J Pediatr. 1992 Sep;121(3):348-54
pubmed: 1517907
J Med Virol. 2014 Sep;86(9):1629-38
pubmed: 24166209
N Engl J Med. 2009 Feb 5;360(6):588-98
pubmed: 19196675
Am J Respir Crit Care Med. 2005 Jan 15;171(2):137-41
pubmed: 15516534
Paediatr Respir Rev. 2013 Jan;13 Suppl 2:S1-8
pubmed: 23269181
Arch Pediatr Adolesc Med. 2012 Aug;166(8):700-6
pubmed: 22473882
N Engl J Med. 2001 Jun 21;344(25):1917-28
pubmed: 11419430
PLoS One. 2016 May 25;11(5):e0155777
pubmed: 27224021
Influenza Other Respir Viruses. 2020 Nov;14(6):630-637
pubmed: 31206246
Influenza Other Respir Viruses. 2020 Nov;14(6):730-738
pubmed: 32533658
Clin Infect Dis. 2012 Mar;54(6):810-7
pubmed: 22247121
Sci Rep. 2018 Jan 17;8(1):995
pubmed: 29343795
World J Clin Pediatr. 2012 Oct 08;1(3):8-12
pubmed: 25254161